The US Court of Appeals for the Federal Circuit reversed a
district court's summary judgment that found a patent was not
obvious because the claimed pH range would not have been
obvious-to-try despite overlapping ranges between the claimed pH
range and the pH range for similar prior art compounds. Valeant
Pharms. Intl. v. Mylan Pharms. Inc., Case No. 18-2097 (Fed.
Cir. Apr. 8, 2020) (Lourie, J.).
Valeant owns a patent directed to stable methylnaltrexone
pharmaceutical preparations that can be useful for reducing the
side effects of opioids. Methylnaltrexone is unstable in aqueous
solutions, but the inventors discovered that when the pH of the
methylnaltrexone solution is adjusted to between 3.0 and 3.5, the
percentage of degradants drops significantly. The patent is listed
in the Orange Book for Relistor®, an injectable drug
used to treat constipation as a side effect of taking opioid
medication.